Brief: Ose Immunotherapeutics H1 Cons. Net Loss At EUR 11.9 Mln

Ose Immunotherapeutics SA

27/09/2023 17:07

Sept 27 (Reuters) - OSE Immunotherapeutics SA  OSE.PA :
    * H1 CONSOLIDATED NET LOSS OF €11,9 MILLION
    * €15 MILLION AVAILABLE CASH AS OF JUNE 30, 2023,
SUPPLEMENTED BY
RESEARCH AND DEVELOPMENT TAX CREDIT OF €5.4 MILLION AND ADDITIVE
FINANCING SECURED POST-H1-2023 FOR ALMOST €14 MILLION
    * H1 OPERATING RESULT OF LOSS EUR 13.5 MILLION VERSUS LOSS
EUR 3.4
MILLION YEAR AGO

Source text for Eikon:  ID:nBw834P12a 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))